Magnesium acetyltaurate has the strongest laboratory evidence for protecting the retinal cells that glaucoma destroys, but no large clinical trial has crowned any single magnesium form as definitively “best” for glaucoma patients. The research landscape is a patchwork of small human studies, animal experiments, and computational models, each pointing to magnesium’s potential through different mechanisms. What makes the question interesting is that the form of magnesium you take probably matters more for eye health than it does for, say, leg cramps, because the relevant targets sit behind the blood-brain and blood-retinal barriers.
Why Magnesium Keeps Showing Up in Glaucoma Research
Glaucoma is not simply “high eye pressure.” While elevated intraocular pressure (IOP) is a major risk factor, many people lose vision despite having normal pressure, and some people with high pressure never develop damage. This has pushed researchers to look beyond pressure-lowering drugs toward the cells that actually die in glaucoma: retinal ganglion cells, the neurons that carry visual information from the eye to the brain. Magnesium turns out to be relevant to their survival through two mostly independent pathways.
The first pathway involves blood flow. The small arteries that feed the optic nerve can constrict excessively in some glaucoma patients, especially those with normal-tension glaucoma or a tendency toward vasospasm. In lab experiments on pig ciliary arteries, magnesium produced complete, dose-dependent relaxation of vessels that had been pre-constricted by endothelin-1, a potent vasoconstrictor implicated in glaucoma damage.1PubMed. Modulation of endothelin-1-induced contractions by magnesium/calcium in porcine ciliary arteries That relaxation was independent of nitric oxide, meaning magnesium was working as a direct calcium antagonist on the vessel wall rather than relying on the usual endothelial signaling.
The second pathway is neuroprotection. When retinal ganglion cells are under stress, they can be killed by excessive activation of NMDA receptors, which flood the cell with calcium. Magnesium ions physically sit in the NMDA receptor channel and block it in a voltage-dependent way, reducing the calcium surge.2PubMed Central. Magnesium neuroprotection in retinal ganglion cells: A computational study of frequency-dependent therapeutic windows and intervention timing This is the same mechanism that makes magnesium relevant in stroke and traumatic brain injury research. In the eye, it means magnesium could slow the excitotoxic cascade that kills ganglion cells even when pressure is under control.
Glaucoma Patients Tend to Be Low in Magnesium
A study comparing glaucoma patients to healthy controls found that serum magnesium levels were roughly half of normal in the glaucoma group, averaging about 1.1 mg/dL compared to 2.4 mg/dL in controls.3Universa Medicina. Decreased magnesium level and membrane potential of glaucoma patients That is a striking difference, not a subtle one. The same study found that cell membrane potential was also significantly lower in glaucoma patients, which fits with magnesium’s role in maintaining electrical stability across cell membranes. Whether low magnesium is a cause, a consequence, or just a fellow traveler of glaucoma remains unclear, but the association gives a practical reason to care about magnesium status if you have the disease.
The Forms That Have Actual Research Behind Them
Most magnesium supplements you find on shelves are designed for general health: muscle relaxation, sleep, bowel regularity. For glaucoma, the question is narrower. You want a form that gets absorbed well, ideally crosses into the nervous system, and has some track record in eye-specific research. Three forms stand out, each for different reasons.
Magnesium Acetyltaurate
This is a compound that pairs magnesium with acetyltaurine, a derivative of the amino acid taurine. It has the most direct retinal evidence of any magnesium form. In rat models of NMDA-induced retinal damage, magnesium acetyltaurate (often abbreviated MgAT) protected retinal ganglion cells by restoring the balance of calcium-regulated proteins that go haywire during excitotoxic injury.4PubMed Central. Protective effect of magnesium acetyltaurate against NMDA-induced retinal ganglion cell loss in rats involves calcium-regulated proteins Treated animals showed better ganglion cell survival and preserved visual function compared to untreated ones.
Separate experiments found that MgAT also reduced nitrosative stress in the retina, and that the combination of magnesium and taurine in a single molecule outperformed taurine alone. The ganglion cell layer was thicker and showed less programmed cell death in MgAT-treated eyes.5PubMed Central. Protective effect of magnesium acetyltaurate and taurine against NMDA-induced retinal damage involves reduced nitrosative stress Additionally, MgAT restored normal concentrations of minerals and trace elements in damaged retinal tissue, suggesting it helps maintain the broader chemical environment that retinal cells need to function.6PubMed. Protective effect of magnesium acetyltaurate against NMDA-induced retinal damage involves restoration of minerals and trace elements homeostasis
The catch is that all of this work is in animals. No published human trial has tested MgAT specifically in glaucoma patients. Still, the consistency of the retinal findings across multiple studies makes it the form most often mentioned by researchers writing about neuroprotective strategies for glaucoma.
Magnesium L-Threonate
This form was developed specifically for its ability to cross the blood-brain barrier and raise magnesium levels inside neurons. It has been described in the integrative ophthalmology literature as a modulator of neuroinflammation with potential protective effects on retinal ganglion cells.7Traditional Medicine. Beyond Pressure: Towards an Integrative Paradigm in Glaucoma Management The logic is straightforward: if the target is neuronal magnesium levels, you want a form that preferentially ends up in neural tissue rather than staying in the bloodstream or being shunted to the gut. Magnesium L-threonate has brain-penetration data from rodent studies in the neuroscience literature, and some clinicians extrapolate that penetration to the retina, which is embryologically part of the central nervous system.
The gap here is even larger than for MgAT. There are no published retinal-specific studies on magnesium L-threonate. Its inclusion in discussions of glaucoma management is based on reasoning by analogy from brain research. That reasoning is plausible, but it is not evidence.
Generic Oral Magnesium (Citrate and Others)
The small human trials that do exist in glaucoma used plain oral magnesium supplements, not specialty forms. One study gave 10 glaucoma patients 121.5 mg of magnesium twice daily for a month. All had vasospasm, confirmed by how their finger capillaries responded to cold. After treatment, visual fields tended to improve, and all three measures of peripheral circulation improved significantly. Blood pressure and heart rate stayed stable.8Ophthalmologica. The Influence of Magnesium on Visual Field and Peripheral Vasospasm in Glaucoma
A separate study of patients with normal-tension glaucoma found that oral magnesium therapy improved visual field parameters after just one month. Mean deviation, a standard measure of overall visual field sensitivity, improved from roughly -3.7 to -2.5 decibels, a meaningful change for a condition where losses tend to be irreversible.9PubMed. The effect of oral magnesium therapy on visual field and ocular blood flow in normotensive glaucoma Interestingly, this study did not find a change in ocular blood flow despite the visual field improvement, which suggests that the benefit may have been neuroprotective rather than circulatory.
Neither study specified the exact form used, which is common in older ophthalmic literature where researchers were more interested in the mineral itself than the carrier molecule. The takeaway is that even generic oral magnesium showed measurable short-term benefits in small groups, though both studies were tiny and lacked placebo controls.
Retinal Venous Pressure and Normal-Tension Glaucoma
A more recent study focused on a specific measurement called retinal venous pressure, which tends to be elevated in normal-tension glaucoma patients with Flammer syndrome, a condition characterized by an exaggerated vascular response to stimuli like cold, stress, or altitude. After six weeks of magnesium supplementation, retinal venous pressure dropped by about 2.15 mmHg, a statistically significant decrease. Eye pressure itself did not change.10hb TIMES Schw Aerztej. The Effect of Magnesium on Retinal Venous Pressure of Patients with Normal-Tension Glaucoma and Flammer Syndrome
This matters because retinal venous pressure is thought to reflect the local vascular environment of the optic nerve head. A drop in venous pressure without a change in IOP suggests magnesium was working on the microcirculation rather than on the plumbing that controls how fluid drains from the eye. For patients with normal-tension glaucoma, where IOP-lowering drugs are already the standard treatment but don’t always stop progression, this is a tantalizing result. Again, the study was small, but it adds to a pattern: magnesium seems to help the eye through blood flow and nerve protection rather than by lowering pressure itself.
Bioavailability Matters More Than You Might Think
Not all magnesium supplements deliver the same amount of usable magnesium to your body. A systematic review of magnesium supplement bioavailability found that organic forms (where magnesium is bound to a carbon-containing molecule like citrate, glycinate, or taurate) are generally better absorbed than inorganic forms (like magnesium oxide or magnesium sulfate), and that absorption decreases as the dose goes up.11PubMed. Bioavailability of magnesium food supplements: A systematic review This is why magnesium oxide, despite being cheap and containing a high percentage of elemental magnesium by weight, is among the least useful forms for actually raising your levels.
Lab testing confirms that these differences in dissolution and absorption are real and measurable. When researchers compared two supplements with opposing results in a gut simulation model, those differences translated directly into different serum magnesium profiles in human volunteers. The better-absorbed supplement showed a roughly 6% rise in serum magnesium over four hours, while the poorly absorbed one barely moved the needle at about a 5% rise with a dramatically smaller total absorption.12PubMed Central. Predicting and Testing Bioavailability of Magnesium Supplements
For glaucoma purposes, this has a practical implication: if you are taking magnesium to support retinal health rather than to relieve constipation, you probably want a well-absorbed organic form rather than a cheap inorganic one. Magnesium citrate and magnesium glycinate are widely available and well-absorbed. Magnesium acetyltaurate combines good absorption with the taurine component that seems to add retinal benefit. Magnesium L-threonate prioritizes brain and neural tissue delivery. Magnesium oxide, carbonate, and sulfate are poor choices if absorption is the goal.
The Contradictory Evidence From Dietary Studies
Here is where things get confusing. While the clinical trials and animal studies point toward magnesium being helpful, at least one large dietary study tells a different story. The Rotterdam Study, a prospective cohort following over 3,500 people aged 55 and older, found that higher dietary magnesium intake was actually associated with a higher risk of developing open-angle glaucoma, with a hazard ratio of 2.25 for the highest versus lowest third of intake.13European Journal of Epidemiology. Nutrient intake and risk of open-Angle glaucoma: The Rotterdam Study The researchers themselves noted this was “less unambiguous to interpret,” which is academic understatement for “we don’t quite know what to make of this.”
A separate analysis using a different dataset reached the opposite conclusion, finding that sufficient dietary calcium, potassium, and magnesium consumption may be protective against glaucoma.14PubMed Central. Association between dietary calcium, potassium, and magnesium consumption and glaucoma
How do you reconcile these? A few possibilities. Dietary magnesium intake, measured by food questionnaires, is notoriously imprecise. People who eat more magnesium-rich foods also eat differently in many other ways, and it is hard to untangle one nutrient from the overall dietary pattern. The Rotterdam cohort was older and Dutch, which introduces population-specific confounders. And dietary magnesium is not the same as supplemental magnesium in a controlled dose. The interventional studies, where patients took defined amounts of magnesium and researchers measured what happened to their visual fields, tell a more consistent story than the observational dietary data. This is a case where the experimental evidence and the epidemiological evidence don’t line up neatly, and it would be a mistake to let one dietary study override the mechanistic and interventional data.
Practical Guidance for Someone Considering Magnesium
If you have glaucoma and are thinking about adding magnesium, a few points are worth keeping in mind. First, magnesium is not a replacement for your prescribed glaucoma treatment. Every study that showed benefits used magnesium as an add-on, not a standalone therapy. IOP-lowering drops, laser procedures, and surgery remain the evidence-based backbone of glaucoma management.
Second, the strongest case for magnesium supplementation is in normal-tension glaucoma, especially if you have signs of vasospasm like cold hands or Raynaud-like symptoms. The clinical studies showing visual field improvement and retinal venous pressure reduction were conducted in this subgroup. If your glaucoma is driven primarily by high IOP without a vascular component, the evidence for magnesium is weaker, though the neuroprotective rationale still applies.
Third, if you choose to supplement, an organic form is preferable. Magnesium acetyltaurate is the best-studied form for retinal protection in animal models, but it can be harder to find and more expensive. Magnesium L-threonate is a reasonable choice if you want neural tissue penetration, though its eye-specific evidence is thin. Magnesium citrate and glycinate are easy to find, well-absorbed, and were likely close to what was used in the human visual field studies. Magnesium oxide is a poor choice for this purpose.
Fourth, dosing in the clinical studies was modest, around 240-300 mg of elemental magnesium per day split into two doses. Higher doses carry a risk of diarrhea and, in people with kidney disease, can lead to dangerous accumulation. Your ophthalmologist and primary care doctor should both know if you are taking magnesium supplements, particularly if you are also on blood pressure medications, since magnesium can modestly lower blood pressure.
A Genetic Layer to the Story
There is an emerging genetic dimension that connects magnesium handling to glaucoma risk. Transient receptor potential melastatin (TRPM) channels are a family of ion channels involved in sensing and transporting magnesium and other cations. A study of genetic variants in TRPM5 found that a specific polymorphism was strongly associated with primary open-angle glaucoma, with one genotype carrying roughly a fivefold increase in risk compared to the reference genotype.15PubMed Central. Association transient receptor potential melastatin channel gene polymorphism with primary open angle glaucoma
TRPM channels regulate how cells handle magnesium and calcium, and variants that alter their function could change how the eye responds to magnesium supplementation. This is speculative territory, and no one is currently genotyping glaucoma patients to guide their magnesium regimen. But it points toward a future where the answer to “which magnesium is best” might depend not just on the supplement form but on your individual biology. For now, the finding reinforces the idea that magnesium metabolism is genuinely intertwined with glaucoma pathophysiology rather than being a tangential nutritional footnote.